Unicancer is the only French hospital network dedicated 100% to the fight against cancer and the only national hospital federation dedicated to cancer research.
It brings together 18 private, non-profit cancer centers (CLCCs) at 20 hospital sites in France, as well as two affiliated member institutions. The CLCCs provide care for nearly 530,000 patients per year (in short stay, HAH and outpatient procedures).
Unicancer is also the leading European academic sponsor of clinical trials in oncology, with 106 active clinical trials supported in 2020 and nearly 7,600 patients included. Unicancer also supports flagship programs that use real-life data to improve knowledge and the evaluation of therapeutic strategies, notably through the ESME platforms, which gather data from more than 76,000 cancer patients.
Recognized as a research leader in France, the Unicancer network boasts a global reputation by producing one third of French publications of international scope in oncology (source: bibliometric study/Thomson Reuters). In 2020, the Unicancer network sponsored up to 700 clinical trials (inclusion or follow-up), more than 14% of CLCC patients are included in clinical trials and more than half of the hospital-based clinical research programs (PHRC) are dedicated to CLCCs.
The 18 CLCCs and Unicancer's R&D department are ISO 9001:2015 certified for their clinical research.
Its role in WeShare
UNICANCER leads the WeShare program and is responsible for the contractual and regulatory fields, the technical development and maintenance of the WeShare platform, its collection and storage, coordination of WeShare’s communication and valorization.